|Dosage Form||Capsule (oral; 150mg and 100mg)|
|Drug Class||Kinase inhibitors|
|Company||Boehringer Ingelheim Pharmaceuticals|
- For the treatment of idiopathic pulmonary fibrosis (IPF).
- For the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
- For the slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).